EXTON, Pa.--(BUSINESS WIRE)--Royal DSM, a global science-based company active in health, nutrition and materials, today announces Mr. Eric Teutsch’s appointment as President of DSM Biomedical effective 16 February 2016. Mr. Teutsch succeeds Mr. Gerard de Reuver who served as the Company’s interim president since November 2015.
As president, Mr. Teutsch will oversee the strategic development and execution of DSM Biomedical’s global activities. Under his leadership, DSM Biomedical will continue to strengthen existing technology platforms and will explore opportunities to form strategic partnerships that complement its activities in the medical device market.
“I am honored to have been appointed President of DSM Biomedical,” said Mr. Teutsch. “The Company has a proven track record of developing innovative solutions for the medical device market and I am excited to drive expansion and solidify our position as the market leader.”
Mr. Teutsch joins DSM from Stryker, where he was Vice President and General Manager of the Orthobiologics Division. In his nearly 30 years at Stryker, Teutsch led the acquisition, integration and operation of ten new product lines and businesses and led four new stand-alone business divisions. He has a proven track record in building and developing highly engaged global leadership teams that consistently gained market share and met or exceeded sales and profit goals.
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com/medical or www.dsm.com.
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.